Floatz logo

Montelukast

Obesity; Endocrine; Diabetes Type 2

Sadat City UniversitySmall moleculeEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Obesity; Endocrine; Diabetes Type 2 cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Montelukast is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
BBB
Indicative ·
73 / 100
View asset →
asthmaDormant
BBB
Indicative ·
73 / 100
View asset →
Fabry diseaseDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →